Prolonged Progression-Free Survival with Partial Disease Regression in Advanced Metastatic Medullary Thyroid Carcinoma Treated with Vandetanib

Prolonged Progression-Free Survival with Partial Disease Regression in Advanced Metastatic Medullary Thyroid Carcinoma Treated with Vandetanib

ABSTRACT: Objective: Medullary thyroid cancer (MTC), derived from thyroidal parafollicular C-cells, is a difficult treatment problem when presenting with advanced and meta-static disease. The recent addition of targeted systemic medical therapy with tyrosine kinase inhibitors has shown great promise...

Full description

Bibliographic Details
Main Authors: Sravanthi Sanivarapu, MD, Zahily Sardiñas, MD, Salini C. Kumar, MD, David S. Rosenthal, MD, Wondwossen Gebre, MD, Minakshi Ramchand, MD
Format: Article
Language:English
Published: Elsevier 2018-09-01
Series:AACE Clinical Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060520301620

Internet

http://www.sciencedirect.com/science/article/pii/S2376060520301620

Similar Items